Capital Research Global Investors reduced its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,446,305 shares of the medical instruments supplier's stock after selling 326,099 shares during the quarter. Capital Research Global Investors owned 10.62% of Insulet worth $1,944,029,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. MML Investors Services LLC grew its position in Insulet by 9.3% in the third quarter. MML Investors Services LLC now owns 2,655 shares of the medical instruments supplier's stock valued at $618,000 after acquiring an additional 225 shares in the last quarter. Virtu Financial LLC acquired a new position in Insulet in the 3rd quarter worth $616,000. Wilmington Savings Fund Society FSB purchased a new position in Insulet in the 3rd quarter valued at about $114,000. Tidal Investments LLC grew its stake in shares of Insulet by 5.2% during the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier's stock valued at $2,180,000 after acquiring an additional 466 shares in the last quarter. Finally, Synovus Financial Corp increased its position in shares of Insulet by 36.1% during the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier's stock worth $682,000 after acquiring an additional 777 shares during the last quarter.
Insider Activity at Insulet
In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company's stock.
Insulet Stock Performance
PODD stock traded up $14.05 on Thursday, reaching $260.54. The company's stock had a trading volume of 271,156 shares, compared to its average volume of 713,936. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $18.30 billion, a P/E ratio of 45.00, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The firm has a fifty day moving average of $261.03 and a two-hundred day moving average of $261.05.
Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. As a group, analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Wells Fargo & Company lifted their price objective on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Piper Sandler upped their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective for the company. Stifel Nicolaus upped their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Finally, TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $292.06.
Check Out Our Latest Report on Insulet
Insulet Company Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Stories
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
